EAU 2023 Prostate Cancer

Viewing 1-20 of 43 articles

EAU 2023: State-of-the-Art Lecture: PARP Inhibitors: For Which Mutations and When?

EAU 2023: State-of-the-Art Lecture: Optimal Treatment Sequencing in the Area of Triplet Therapies for Hormone-Sensitive Disease

EAU 2023: Debate: Is There Any Added Value of Docetaxel in Combination with ADT and ARPI for the Treatment of mHSPC?

EAU 2023: State-of-the-Art Lecture: What Are the Best Predictive Factors for Successful Treatment with Lu PSMA?

EAU 2023: State-of-the-Art Lecture: When and How to Sequence (Molecular Testing)?

EAU 2023: Patient with High-Risk Localized Disease, M0 on Conventional Imaging but One Bone Lesion on PSMA PET/CT: Arguments for a Surgical Approach +/- Radiotherapy +/- Systemic Treatment

EAU 2023: Debate: Low-Volume Disease at Conventional Imaging, 5 Bone Metastases at PSMA PET/CT

EAU 2023: Patient with High-Risk Localized Disease, M0 on Conventional Imaging but One Bone Lesion on PSMA PET/CT: Arguments for a Radiotherapeutic Approach +/- Systemic Treatment

EAU 2023: Patient with High-Risk Localized Disease, M0 on Conventional Imaging but One Bone Lesion on PSMA PET/CT: Subtypes of Prostate Cancer and How They Change our Management

EAU 2023: Patient with High-Risk Localized Disease, M0 on Conventional Imaging but One Bone Lesion on PSMA PET/CT: Systemic Therapy: What and for how long?

EAU 2023: State-of-the-Art Lecture: Patient-Related Factors That Guide Treatment Decisions

EAU 2023: State-of-the-Art Lecture When and How to Stage?

EAU 2023: Debate: High-Risk BRCA Mutated Case with N0 M0 at Conventional Imaging and Multiple cN1 at PSMA: What to Do?

EAU 2023: LuTectomy: A Prospective Study of Dosimetry, Safety and Potential Benefit of Upfront 177Lu-PSMA-617 Radioligand Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer

EAU 2023: Patient with High-Risk Localized Disease, M0 on Conventional Imaging but One Bone Lesion on PSMA PET/CT: How to Treat a Frail and Elderly Patient in this Situation

EAU 2023: State-of-the-Art Lecture: Germ Line Testing in Hormone-Sensitive Prostate Cancer: When and Why?

EAU 2023: PSMA-PET in Local Evaluation of the Prostate for Active Surveillance? No

EAU 2023: State-of-the-Art Lecture: In Which Patients with Low-Volume mHSPC Should We Use Metastases-Directed Therapy?

EAU 2023: PSMA-PET in Local Evaluation of the Prostate for Active Surveillance? Yes

EAU 2023: How to Manage Active Surveillance - Do We Need a Genetic Biopsy Test to Promote AS in GG2 Cancers?

1
2
3